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Depression after Cyproheptadine: 
MAO Treatment 
To the Editor: 
Cyproheptadine has been reported to be effec- 
tive in the treatment of anorgasmia induced by the 
administration of tricyclic antidepressants (Sovner 
1984; Steele and Howell 1986), monoamine oxi- 
dase inhibitors (MAOIs) (DeCastro 1985), or 
fluoxetine (McCormick et al 1990). It has been 
postulated that cyproheptadine's efficacy in treating 
this symptom is caused by the blockade of seroto- 
nin receptors. 
The administration of cyproheptadine for the treat- 
ment of antidepressant-induced sexual dysfunction 
has recently been associated with a recurrence of 
depressive symptomatology in a series of three pa- 
tients treated with fluoxetine (Feder 1991), as well 
as with the reversal of therapeutic benefit in two pa- 
tients with bulimia nervosa, also treated with fluox- 
etine (Goldboom and Kennedy 1991). 
We report here a case of recurrence of depressive 
symptoms after administration of cyptoheptadine in 
a patient who received full therapeutic benefit from 
tseatment with pheneizine. 
Mr. C. is a 37-year-old man who presented for 
diagnosis and treatment of chronic depressive symp- 
tomatology. Upon evaluation, he was severely de- 
pressed, with a blunted affect, as well as mood ir- 
ritability, and a history of chronic impulsive self- 
injurious behavior, usually during the periods of more 
severe depression. A 17-item Hamilton Depression 
Rating Scale (HDRS) score of 38 was obtained on 
initial evaluation. Although no actual suicide attempts 
were reported, he described almost constant suicidal 
ideation, which he resisted by increasing his physical 
activity until exhaustion. 
During the year prior to evaluation, he had been 
attending weekly outpatient psychotherapy. Concom- 
itant with the psychotherapeutic intervention, several 
medication trials had been attempted, including de- 
sipramine, imipramine and nortriptyline, without re- 
lief of depressive symptoms. Trazodone was reported 
of limited benefit, with a mild reduction in depressive 
symptomatology, but severe sedation and orthostatic 
hypotension necessitated discontinuation of this agent. 
A trial of fluoxetine significantly reduced symptom- 
atology after 6 weeks, but was also poorly tolerated 
due to severe agitation and anxiety. 
In addition to a referral for cognitive-behavioral 
therapy, phenelzine was initiated, to a maximum dose 
of 75 mg per day. After 5 weeks on this regimen, 
his depressive symptomatology remitted (HDRS score 
= 4). Suicidal ideation and self-injurious behavior, 
as well as the demanding, impulsive, and irritable 
style noted in the initial presentation, were also mark- 
edly diminished. 
Concomitant with the resolution of his depressive 
symptomatology, the patient reported difficulties in 
sexual activity, with delayed ejaculation that later 
progressed to anorgasmia. Treatment with cyprohep- 
tadine was initiated at a daily dose of 4 mg in an 
attempt to reduce his sexual dysfunction. Within 3 
days of initiating this medication, nearly complete 
recurrence of depressive symptomatology was ob- 
served. No improvement of anorgasmia was reported 
1178 BIOL PSYCHIATRY 
1992;31:1172-I 183 
Correspondence 
by the patient. Discontinuation of cyproheptadine 
promptly reduced his depressive symptoms (HDRS 
scores decreased from 22, 5 days after cessation of 
cyproheptadipe, to 6, 12 days after discontinuing 
treatment). At the present time, the patient reports a 
moderate degree of delayed ejaculation, although he 
is no longer anorgasmic. 
We report here an instance of recurrence of de- 
pressive symptomatology 3 days after the adminis- 
tration of cyproheptadine in a patient who had re- 
sponded fully to treatment with the MAOI phenelzine. 
This phenomenon has been reported previously, in a 
similarly rapid time course (few hours to 4 days), in 
three patients responsive to the serotonin-reuptake 
blocker, fluoxetine (Feder 1991). Cyproheptadine may 
lead to a revetsal of clinical benefit when adminis- 
tered for the treatment of antidepressant-induced an- 
orgasmia. Close observation of patients treated with 
this regimen is suggested. 
John Kar Zubieta 
Mark A. Demitrack 
Department of Psychiatry 
University of Michigan Medical Center 
Ann Arbor, Michigan 
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Sodium Valproate Augmentation 
of Fluoxedne or Fluvoxamine Effects 
To the Fditor: 
t:ontaine et al (1991) described the addition of lith- 
ium to fluoxetine in the treatment of refractory depres- 
sion. This is likely to be a major advance if lithium 
augments the action of fluoxetine without producing a 
potf~ntially dangerous hyperserotonin syndrome (CSM 
1919). For cases in whom there are contraindications 
to the use of lithium carbonate, the introduction of so- 
dium valproate may be considered. The use of sodium 
valproate in the treat~ient of affective illness has been 
previously described (Emrich et al 1985), but it also 
appears to have an augmenting effect on the specific 
serotonin reuptake inhibitors fluoxetine and fluvox- 
amine. Two cases are described in some detail. 
Case 1 
A ~7-year-old woman was referred with a 2- 
month history of panic attacks and depression with 
weight loss, sleep disturbance, and feelings of guilt. 
The general practitioner treated the woman with 
imipramine, which caused a rash, and benzodiaze- 
pines. Treatment with clomipramine, then with 
clomipramine and tryptophan, was not completely 
effective and she was unable to stop the diazepam 
because of continuing feelings of anxiety. There was 
also a severe tremor so these drugs were gradually 
withdrawn. A course of electrconvulsive therapy 
(ECT) helped temporarily but was followed by a 
rapid deterioration. Eighteen months after initial re- 
ferral, fluoxetine was started and was increased 
gradually to 20 mg TID, and nifedipine, which might 
have been maintaining the depression, was discon- 
tinued. The patient was discharged on fluoxetine 60 
mg mane only, but 3 weeks later reported severe 
depression, wakening with panic at 5:00 A.M., diur- 
nal variation of mood, and poor appetite. Fluoxe- 
tine was reduced to 20 mg mane, sodium valproate 
was added, and 4 weeks later there was a marked 
improvement. Six weeks after the introduction of 
valproate the patient was completely free fr~,m pan- 
